Todd Knepper

Dr. Todd Knepper

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TKTodd Knepper
Todd Knepper
MMMeagan Montesion
Meagan Montesion
JRJeffery S. Russell
Jeffery S. Russell
ESEthan S. Sokol
Ethan S. Sokol
GFGarrett M. Frampton
Garrett M. Frampton
ABAndrew S Brohl
Andrew S Brohl
Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy, which has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we perform the largest genomics study in MCC to date to characterize the molecular landscape and evaluate for clinical and molecular correlates to immune checkpoint inhibitor response. Experimental Design: Comprehensive molecular profiling was performed on 317 tumors from patients with MCC, including the evaluation of oncogenic mutations, tumor mutational burden (TMB), mutational signatures, and the Merkel cell polyomavirus (MCPyV). For a subset of 57 patients, a retrospective analysis was conducted to evaluate for clinical and molecular correlates to immune checkpoint inhibitor response and disease survival. Results: Genomic analyses revealed a bimodal distribution in TMB, with 2 molecularly distinct subgroups. Ninety-four percent (n = 110) of TMB-high specimens exhibited an ultraviolet light (UV) mutational signature. MCPyV genomic DNA sequences were not identified in any TMB-high cases (0/117), but were in 63% (110/175) of TMB-low cases. For 36 evaluable patients treated with checkpoint inhibitors, the overall response rate was 44% and response correlated with survival at time of review (100% vs. 20%, P < 0.001). Response rate was 50% in TMB-high/UV-driven and 41% in TMB-low/MCPyV-positive tumors (P = 0.63). Response rate was significantly correlated with line of therapy: 75% in first-line, 39% in second-line, and 18% in third-line or beyond (P = 0.0066). PD-1, but not PD-L1, expression was associated with immunotherapy response (77% vs. 21%, P = 0.00598, for PD-1 positive and negative, respectively). Conclusions: We provide a comprehensive genomic landscape of MCC and demonstrate clinicogenomic associates of immunotherapy response.

9 May 2018 in Nature
Verified
Journal Article
Closed access
TKTodd Knepper
Todd Knepper
HMHoward L. McLeod
Howard L. McLeod

1 December 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CCCatherine C. Coombs
Catherine C. Coombs
NGNancy K. Gillis
Nancy K. Gillis
XTXianming Tan
Xianming Tan
JBJonathan S. Berg
Jonathan S. Berg
MBMarkus Ball
Markus Ball
EPEric Padron
Eric Padron
Purpose: In this era of precision-based medicine, for optimal patient care, results reported from commercial next-generation sequencing (NGS) assays should adequately reflect the burden of somatic mutations in the tumor being sequenced. Here, we sought to determine the prevalence of clonal hematopoiesis leading to possible misattribution of tumor mutation calls on unpaired Foundation Medicine NGS assays. Experimental Design: This was a retrospective cohort study of individuals undergoing NGS of solid tumors from two large cancer centers. We identified and quantified mutations in genes known to be frequently altered in clonal hematopoiesis (DNMT3A, TET2, ASXL1, TP53, ATM, CHEK2, SF3B1, CBL, JAK2) that were returned to physicians on clinical Foundation Medicine reports. For a subset of patients, we explored the frequency of true clonal hematopoiesis by comparing mutations on Foundation Medicine reports with matched blood sequencing. Results: Mutations in genes that are frequently altered in clonal hematopoiesis were identified in 65% (1,139/1,757) of patients undergoing NGS. When excluding TP53, which is often mutated in solid tumors, these events were still seen in 35% (619/1,757) of patients. Utilizing paired blood specimens, we were able to confirm that 8% (18/226) of mutations reported in these genes were true clonal hematopoiesis events. The majority of DNMT3A mutations (64%, 7/11) and minority of TP53 mutations (4%, 2/50) were clonal hematopoiesis. Conclusions: Clonal hematopoiesis mutations are commonly reported on unpaired NGS testing. It is important to recognize clonal hematopoiesis as a possible cause of misattribution of mutation origin when applying NGS findings to a patient9s care. See related commentary by Pollyea, p. 5790

1 February 2017 in The Oncologist
Verified
Journal Article
Closed access
PDF file
TKTodd Knepper
Todd Knepper
GBGillian C. Bell
Gillian C. Bell
JHJ. Kevin Hicks
J. Kevin Hicks
EPEric Padron
Eric Padron
JTJamie K. Teer
Jamie K. Teer
CWChristine M. Walko
Christine M. Walko
Background: The increasing practicality of genomic sequencing technology has led to its incorporation into routine clinical practice. Successful identification and targeting of driver genomic alterations that provide proliferative and survival advantages to tumor cells have led to approval and ongoing development of several targeted cancer therapies. Within many major cancer centers, molecular tumor boards are constituted to shepherd precision medicine into clinical practice.Materials and Methods: In July 2014, the Clinical Genomics Action Committee (CGAC) was established as the molecular tumor board companion to the Personalized Medicine Clinical Service (PMCS) at Moffitt Cancer Center in Tampa, Florida. The processes and outcomes of the program were assessed in order to help others move into the practice of precision medicine.Results: Through the establishment and initial 1,400 patients of the PMCS and its associated molecular tumor board at a major cancer center, five practical lessons of broad applicability have been learned: transdisciplinary engagement, the use of the molecular report as an aid to clinical management, clinical actionability, getting therapeutic options to patients, and financial considerations. Value to patients includes access to cutting-edge practice merged with individualized preferences in treatment and care.Conclusions: Genomic-driven cancer medicine is increasingly becoming a part of routine clinical practice. For successful implementation of precision cancer medicine, strategically organized molecular tumor boards are critical to provide objective evidence-based translation of observed molecular alterations into patient-centered clinical action. Molecular tumor board implementation models along with clinical and economic outcomes will define future treatment standards.

25 August 2016 in Oncotarget
Verified
Journal Article
Open access
CZChengfang Zhou
Chengfang Zhou
XCXiang Chen
Xiang Chen
WZWeiqi Zeng
Weiqi Zeng
CPCong Peng
Cong Peng
GHGang Huang
Gang Huang
HMHoward L. McLeod
Howard L. McLeod
Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway

5 April 2021 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
NDNing Dong
Ning Dong
FTFranco Castillo Tokumori
Franco Castillo Tokumori
LILeidy Isenalumhe
Leidy Isenalumhe
YZYumeng Zhang
Yumeng Zhang
ATAnkita Tandon
Ankita Tandon
LSLubomir Sokol
Lubomir Sokol